Diagnosis of chronic lymphoproliferative disorders by flow cytometry using four-color combinations for immunophenotyping: A proposal of the brazilian group of flow cytometry (GBCFLUX)

• Autor(a) principal: Sales, M. M.
• Data de Publicação: 2017
• Outros Autores: Ferreira, S. I. A. C. P., Ikoma, M. R. V., Sandes, A. F., Beltrame, M. P., Bacal, N. S., Silva, M. C. A., Malvezzi, M., Lorand-Metze, I. G. H., Orfao, A., Yamamoto, M. [UNIFESP]
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://dx.doi.org/10.1002/cyto.b.21396; http://repositorio.unifesp.br/handle/11600/51317
• topic: chronic lymphoproliferative disorders; flow cytometry; GBCFLUX; monoclonal antibody panel; lymphoma; multiple myeloma

BackgroundMultiparametric flow cytometry (MFC) is a powerful tool for the diagnosis of hematological malignancies and has been useful for the classification of chronic lymphoproliferative disorders (CLPD) according to the WHO criteria. Following the purposes of the Brazilian Group of Flow Cytometry (GBCFLUX), the aim of this report was to standardize the minimum requirements to achieve an accurate diagnosis in CLPDs, considering the different economic possibilities of the laboratories in our country. Most laboratories in Brazil work with 4-fluorescence flow cytometers, which is why the GBCFLUX CLPD Committee has proposed 4-color monoclonal antibody (MoAb) panels. Methods/ResultsPanels for screening and diagnosis in B, T and NK lymphoproliferative disorders were developed based on the normal differentiation pathways of these cells and the most frequent phenotypic aberrations. Important markers for prognosis and for minimal residual disease (MRD) evaluation were also included. The MoAb panels presented here were designed based on the diagnostic expertise of the participating laboratories and an extensive literature review. ConclusionThe 4-color panels presented to aid in the diagnosis of lymphoproliferative neoplasms by GBCFLUX aim to provide clinical laboratories with a systematic, step-wise, cost-effective, and reproducible approach to obtain an accurate immunophenotypic diagnosis of the most frequent of these disorders. (c) 2016 International Clinical Cytometry Society